Advertisement

Topics

Cytokinetics inches forward with heart failure program

06:08 EDT 2 Aug 2017 | BioPharmaDive

Amgen and the smaller biotech have been developing omecamtiv mercabil since 2006, pushing through a clinical setback and dimming commercial prospects for the class. 

Original Article: Cytokinetics inches forward with heart failure program

NEXT ARTICLE

More From BioPortfolio on "Cytokinetics inches forward with heart failure program"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...